Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results.

Naismith, Robert T; Hendin, Barry; Wray, Sibyl; Huang, DeRen; Gaudenzi, Fiorenza; Dong, Qunming; Sperling, Bjørn; Mann, Monica; Werneburg, Brian

Naismith, Robert T; Hendin, Barry; Wray, Sibyl; Huang, DeRen; Gaudenzi, Fiorenza; Dong, Qunming; Sperling, Bjørn; Mann, Monica; Werneburg, Brian.

Afiliación

Naismith RT; Department of Neurology, Washington University in St Louis, USA.
Hendin B; Phoenix Neurological Associates, USA.
Wray S; Hope Neurology, USA.
Huang D; Mount Carmel Neuroscience and MDH Research, USA.
Gaudenzi F; Biogen, USA.
Dong Q; Biogen, USA.
Sperling B; Biogen, USA.
Mann M; Biogen, USA.
Werneburg B; Biogen, USA.

Mult Scler J Exp Transl Clin ; 5(1): 2055217318822148, 2019.

Article en En | MEDLINE | ID: mdl-30729026

Palabras clave

Beta-interferon; multiple sclerosis; peginterferon beta-1a; pegylated; relapsing multiple sclerosis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Idioma: En Revista: Mult Scler J Exp Transl Clin Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google